Kyntra Bio, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Kyntra Bio is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $5.22, 53.3% below its 52-week high and below its 200-day average, which is falling.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More about the company

$5.22

+0.19% today

$21.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is KYNB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 26w

S4 21w

S4 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 20w → S1 12w → S2 3w → S3 9w → S4 26w → S1 12w → S4 21w → S1 5w → S2 8w → S3 9w → S4 25w → S1 11w → S4 3w current

Total tracked: 165 weeks across 13 stage runs.

KYNB among Biotechnology359th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…359	KYNBKyntra Bio, Inc.	Stage 4 · wk 3	22	−28.0%

vs 52W High

-53.3%

$4.85 lo$11.18 hi

53.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.9%

200 DMA: $7.24 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.40x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-28.0%

-25.7%

-25.5%

YTD

-43.0%

-53.2%

Scan Membership

Breakout Watch

Latest: 2024-04-01

6 appearances in last 60 days. First seen: 2019-03-15.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.40x

2026-10-21S4

Wk 3 · Vol 0.44x

2026-10-20S4

Wk 3 · Vol 0.57x

2026-10-19S4

Wk 3 · Vol 0.92x

2026-10-16S4

Wk 2 · Vol 1.27x

2026-10-15S4

Wk 2 · Vol 1.42x

2026-10-14S4

Wk 2 · Vol 1.69x

2026-10-13S4

Wk 2 · Vol 0.74x

2026-10-12S4

Wk 2 · Vol 1.12x

2026-10-09S4

Wk 1 · Vol 0.31x

2026-10-08S4

Wk 1 · Vol 0.72x

2026-10-07S4

Wk 1 · Vol 0.81x

Moving averages & range

50 DMA

$6.98

200 DMA

$7.24

52W High

$11.18

52W Low

$4.85

5D Low

$4.85

Resistance levels (recent highs)

20d High

$6.94

60d High

$8.55

120d High

$8.55

250d High

$11.12

Next resistance

+33.0%

to 20d High

Dividend Yield

0.00%

P/B -0.7

Kyntra Bio: quick answers

What stage is Kyntra Bio in?

As of Oct 22, 2026, Kyntra Bio (KYNB) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean

Is Kyntra Bio in an uptrend?

No. Kyntra Bio is in a Stage 4 downtrend. It trades 27.9% below its 200-day average, which is falling.

How far is Kyntra Bio from its 52-week high?

Kyntra Bio closed at $5.22 on Oct 22, 2026, 53.3% below its 52-week high of $11.18. Its 52-week low is $4.85.

How has Kyntra Bio performed over the past year?

As of Oct 22, 2026, Kyntra Bio is down 53.2% over the past year and down 43.0% so far in 2026.

Which sector and industry is Kyntra Bio in?

Kyntra Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.